Skip to main navigation Skip to search Skip to main content

Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination

  • Snigdha Nutalapati
  • , Garima Gupta
  • , Gerhard C. Hildebrandt

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.

Original languageEnglish
Article numbere05035
JournalClinical Case Reports
Volume9
Issue number11
DOIs
StatePublished - Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • SARS-CoV2 vaccination
  • immune thrombocytopenia
  • mycophenolate mofetil
  • romiplostim

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination'. Together they form a unique fingerprint.

Cite this